GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Progyny Inc (NAS:PGNY) » Definitions » Cash Conversion Cycle

PGNY (Progyny) Cash Conversion Cycle : 34.82 (As of Sep. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Progyny Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Progyny's Days Sales Outstanding for the three months ended in Sep. 2024 was 91.45.
Progyny's Days Inventory for the three months ended in Sep. 2024 was 0.
Progyny's Days Payable for the three months ended in Sep. 2024 was 56.63.
Therefore, Progyny's Cash Conversion Cycle (CCC) for the three months ended in Sep. 2024 was 34.82.


Progyny Cash Conversion Cycle Historical Data

The historical data trend for Progyny's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Progyny Cash Conversion Cycle Chart

Progyny Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Conversion Cycle
Get a 7-Day Free Trial 21.28 23.18 27.35 36.60 30.39

Progyny Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 31.88 31.17 34.38 34.12 34.82

Competitive Comparison of Progyny's Cash Conversion Cycle

For the Health Information Services subindustry, Progyny's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Progyny's Cash Conversion Cycle Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Progyny's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Progyny's Cash Conversion Cycle falls into.



Progyny Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Progyny's Cash Conversion Cycle for the fiscal year that ended in Dec. 2023 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=80.8+0-50.41
=30.39

Progyny's Cash Conversion Cycle for the quarter that ended in Sep. 2024 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=91.45+0-56.63
=34.82

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Progyny  (NAS:PGNY) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Progyny Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Progyny's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Progyny Business Description

Traded in Other Exchanges
N/A
Address
1359 Broadway, New York, NY, USA, 10018
Progyny Inc is a company engaged in specializing in fertility and family building benefits solutions. Its clients include employers across various industries. The fertility benefits solution consists of the treatment services (Smart Cycles), access to the Progyny network of high-quality fertility specialists that perform the Smart Cycle treatments and active management of the selective network of high-quality provider clinics.
Executives
Michael E Sturmer officer: President 48 LEDYARD RD, WEST HARTFORD CT 06117
Cheryl Scott director 800 N. GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
Mark S. Livingston officer: Chief Financial Officer C/O PROGYNY, INC., 1359 BROADWAY, 2ND FL, NEW YORK NY 10018
David J Schlanger director, officer: Executive Chairman C/O PROGYNY, INC., 1359 BROADWAY, 2ND FLOOR, NEW YORK NY 10018
Kevin K Gordon director 155 S LIMERICK RD, LIMERICK PA 19468
Tpg Gp A, Llc 10 percent owner 301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102
Peter Anevski officer: Chief Executive Officer C/O PROGYNY, INC., 1359 BROADWAY, 2ND FLOOR, NEW YORK NY 10018
Norman Payson director 800 N. GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
Allison Swartz officer: EVP, GC C/O PROGYNY, INC., 1359 BROADWAY, NEW YORK NY 10018
Lloyd H Dean director 185 BERRY STREET, SUITE 300, SAN FRANCISCO CA 94107
Monice Barbero officer: EVP, GC and Secretary C/O PROGYNY, INC., 1359 BROADWAY, NEW YORK NY 10018
Jon Winkelried 10 percent owner C/O GOLDMAN, SACHS & CO., 85 BROAD STREET, NEW YORK NY 10004
Beth C Seidenberg director
Jennifer Bealer officer: EVP, General Counsel C/O PROGYNY, INC., 245 5TH AVENUE, NEW YORK NY 10016
Malissia Clinton director 333 THREE D SYSTEMS CIRCLE, ROCK HILL SC 29730